An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Key facts
- Study ID
- NCT06952634
- Run by
- Alumis Inc
- People needed
- 32
- Starts
- 2025-04-29
- Expected to finish
- 2026-03-24
- Last updated by the study team
- 2026-05-12
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orange County Research Center — Lake Forest, California, United States
- Panax Clinical Research — Miami Lakes, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- Alliance for Multispecialty Research — Knoxville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.